Compare Alcon AG (ALC) vs Amplitude Inc (AMPL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Amplitude Inc — how do they compare? Alcon AG trades at $66.79 (market cap $32.69B), while Amplitude Inc trades at $9 (market cap $1.21B). The key difference: Alcon AG is far larger — about 27× Amplitude Inc's market cap, and Alcon AG pays a 0.54% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.
| ALC | AMPL | |
|---|---|---|
Market Cap | $32.69B | $1.21B |
Sector | Health | Technology |
52-Week High | $92.22 | $13.29 |
52-Week Low | $62.02 | $5.61 |
Enterprise Value | $36.28B | $1.04B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Amplitude (AMPL) trades at $9.16, up 3.62% on the day, with a bullish technical signal from moving averages. Revenue growth is solid at $343M in 2025, but net losses persist at -$89M. Analyst consensus is 66.7% buy with a $9.00 target. Recent news highlights improving fundamentals but also legal investigations.
The outlook is mixed: strong revenue growth and analyst support offer upside, but profitability challenges and legal risks pose headwinds. Investors should weigh the bullish technicals and growth potential against ongoing losses and regulatory scrutiny for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →
